Zacks: Brokerages Expect TG Therapeutics, Inc. (NASDAQ:TGTX) Will Post Quarterly Sales of $590,000.00

Brokerages forecast that TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) will post sales of $590,000.00 for the current quarter, Zacks reports. Three analysts have issued estimates for TG Therapeutics’ earnings, with estimates ranging from $40,000.00 to $1.34 million. TG Therapeutics reported sales of $1.55 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 61.9%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that TG Therapeutics will report full-year sales of $18.99 million for the current year, with estimates ranging from $3.20 million to $55.71 million. For the next financial year, analysts expect that the company will report sales of $101.04 million, with estimates ranging from $46.28 million to $163.80 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTXGet Rating) last posted its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.08). The company had revenue of $2.32 million during the quarter, compared to analysts’ expectations of $9.90 million. TG Therapeutics had a negative return on equity of 101.11% and a negative net margin of 5,204.07%. During the same quarter in the previous year, the company earned ($0.71) EPS.

Several equities analysts recently issued reports on TGTX shares. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 26th. StockNews.com assumed coverage on TG Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of TG Therapeutics in a report on Monday. B. Riley decreased their target price on TG Therapeutics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, April 19th. Finally, HC Wainwright cut their price target on TG Therapeutics from $68.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, April 18th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $22.75.

Institutional investors have recently modified their holdings of the company. PSI Advisors LLC purchased a new position in shares of TG Therapeutics during the third quarter valued at about $70,000. Macquarie Group Ltd. lifted its holdings in shares of TG Therapeutics by 44.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,160 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 1,277 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of TG Therapeutics in the 4th quarter valued at about $99,000. Exane Derivatives bought a new position in shares of TG Therapeutics in the 1st quarter valued at about $54,000. Finally, Baldwin Brothers LLC MA lifted its holdings in shares of TG Therapeutics by 250.0% in the 1st quarter. Baldwin Brothers LLC MA now owns 7,000 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 70.52% of the company’s stock.

TGTX stock traded up $0.33 during midday trading on Friday, hitting $6.04. The company’s stock had a trading volume of 2,957,288 shares, compared to its average volume of 2,613,822. The company has a market cap of $872.48 million, a PE ratio of -2.17 and a beta of 2.25. TG Therapeutics has a 12 month low of $5.51 and a 12 month high of $41.00. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.28. The firm’s 50-day moving average is $8.62 and its 200-day moving average is $15.12.

About TG Therapeutics (Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Further Reading

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.